Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QHRD211
- Development stage
- Phase 2
- Lead developer
- Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
QHRD211 is a long-acting recombinant human growth hormone (rhGH) developed by Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute for the treatment of pediatric growth hormone deficiency (PGHD). The drug is a PEGylated formulation of somatropin, designed to extend the circulating half-life of the hormone and allow for once-weekly subcutaneous administration, compared to the daily injections required by conventional rhGH therapies. QHRD211 acts as an agonist at the growth hormone receptor (GHR), triggering the JAK2-STAT5 signaling pathway to stimulate the production of insulin-like growth factor 1 (IGF-1), which promotes linear bone growth and metabolic regulation. It is currently in Phase 3 clinical development in China.
- Other names
- Long-acting recombinant human growth hormonePEGylated recombinant human growth hormone
Beyond the preview
Go deeper on QHRD211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QHRD211.